IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
0.7940
-0.0106 (-1.32%)
At close: Oct 27, 2025, 4:00 PM EDT
0.7900
-0.0040 (-0.50%)
After-hours: Oct 27, 2025, 6:40 PM EDT
IceCure Medical Employees
As of December 31, 2024, IceCure Medical had 66 total employees, including 64 full-time and 2 part-time employees. The number of employees decreased by 11 or -14.29% compared to the previous year.
Employees
66
Change (1Y)
-11
Growth (1Y)
-14.29%
Revenue / Employee
$42,227
Profits / Employee
-$236,061
Market Cap
54.74M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66 | -11 | -14.29% |
| Dec 31, 2023 | 77 | 5 | 6.94% |
| Dec 31, 2022 | 72 | 8 | 12.50% |
| Dec 31, 2021 | 64 | 17 | 36.17% |
| Dec 31, 2020 | 47 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ICCM News
- 14 days ago - IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances - PRNewsWire
- 18 days ago - IceCure Medical to Attend the 2025 Maxim Growth Summit - PRNewsWire
- 21 days ago - IceCure Medical Ltd - Special Call - Seeking Alpha
- 24 days ago - IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care - PRNewsWire
- 24 days ago - IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above - PRNewsWire
- 27 days ago - IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented - PRNewsWire
- 5 weeks ago - IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented - PRNewsWire
- 5 weeks ago - IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes - PRNewsWire